2v3e: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 3: | Line 3: | ||
<StructureSection load='2v3e' size='340' side='right'caption='[[2v3e]], [[Resolution|resolution]] 2.00Å' scene=''> | <StructureSection load='2v3e' size='340' side='right'caption='[[2v3e]], [[Resolution|resolution]] 2.00Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[2v3e]] is a 2 chain structure with sequence from [ | <table><tr><td colspan='2'>[[2v3e]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=2V3E OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=2V3E FirstGlance]. <br> | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=NND:(2R,3R,4R,5S)-2-(HYDROXYMETHYL)-1-NONYLPIPERIDINE-3,4,5-TRIOL'>NND</scene>, <scene name='pdbligand=PO4:PHOSPHATE+ION'>PO4</scene>, <scene name='pdbligand=FUC:ALPHA-L-FUCOSE'>FUC</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[1ogs|1ogs]], [[1y7v|1y7v]], [[2f61|2f61]], [[2j25|2j25]], [[2v3d|2v3d]], [[2v3f|2v3f]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat"><div style='overflow: auto; max-height: 3em;'>[[1ogs|1ogs]], [[1y7v|1y7v]], [[2f61|2f61]], [[2j25|2j25]], [[2v3d|2v3d]], [[2v3f|2v3f]]</div></td></tr> | ||
<tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='activity'><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[https://en.wikipedia.org/wiki/Glucosylceramidase Glucosylceramidase], with EC number [https://www.brenda-enzymes.info/php/result_flat.php4?ecno=3.2.1.45 3.2.1.45] </span></td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=2v3e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2v3e OCA], [https://pdbe.org/2v3e PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=2v3e RCSB], [https://www.ebi.ac.uk/pdbsum/2v3e PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=2v3e ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Evolutionary Conservation == | == Evolutionary Conservation == | ||
| Line 30: | Line 30: | ||
==See Also== | ==See Also== | ||
*[[Acid-beta-glucosidase|Acid-beta-glucosidase]] | *[[Acid-beta-glucosidase|Acid-beta-glucosidase]] | ||
*[[Acid-ò-glucosidase 3D structures|Acid-ò-glucosidase 3D structures]] | *[[Acid-ò-glucosidase 3D structures|Acid-ò-glucosidase 3D structures]] | ||
*[[Beta-glucosidase|Beta-glucosidase]] | *[[Beta-glucosidase|Beta-glucosidase]] | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:37, 23 March 2022
acid-beta-glucosidase with N-nonyl-deoxynojirimycin
| ||||||||||||
Proteopedia Page Contributors and Editors (what is this?)
Categories:
- Glucosylceramidase
- Human
- Large Structures
- Aviezer, D
- Brumshtein, B
- Butters, T D
- Futerman, A H
- Greenblatt, H M
- Shaaltiel, Y
- Silman, I
- Sussman, J L
- Acid-beta-glucosidase
- Alternative splicing
- Disease mutation
- Gaucher disease
- Glycoprotein
- Glycosidase
- Hydrolase
- Lipid metabolism
- Lysosome
- Membrane
- N-nonyl-deoxynojirimycin
- N-nonyl-deoxynojirimycinalternative initiation
- Pharmaceutical
- Polymorphism
- Sphingolipid metabolism
